These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20237029)

  • 1. Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial.
    Liu B; Kuang A; Huang R; Zhao Z; Zeng Y; Wang J; Tian R
    J Nucl Med; 2010 Apr; 51(4):618-23. PubMed ID: 20237029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
    Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
    J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
    Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
    J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
    Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
    Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
    Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
    J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer?
    Fallahi B; Beiki D; Abedi SM; Saghari M; Fard-Esfahani A; Akhzari F; Mokarami B; Eftekhari M
    Nucl Med Commun; 2013 Aug; 34(8):777-86. PubMed ID: 23708871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
    Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
    J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer.
    Doi SA; Woodhouse NJ
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):765-73. PubMed ID: 10848882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
    Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer: a randomized-controlled trial.
    Upadhyaya A; Zhou P; Meng Z; Wang P; Zhang G; Jia Q; Tan J; Li X; Hu T; Liu N; Wang S; Liu X; Wang H; Zhang C; Zhao F; Yan Z; Wang X; Zhang X; Zhang W
    Nucl Med Commun; 2017 Nov; 38(11):891-903. PubMed ID: 28806348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer.
    Jentzen W; Schneider E; Freudenberg L; Eising EG; Görges R; Müller SP; Brandau W; Bockisch A
    Nucl Med Commun; 2006 Aug; 27(8):669-76. PubMed ID: 16829767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer.
    Johansen K; Woodhouse NJ; Odugbesan O
    J Nucl Med; 1991 Feb; 32(2):252-4. PubMed ID: 1992028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters.
    Huysmans DA; Buijs WC; van de Ven MT; van den Broek WJ; Kloppenborg PW; Hermus AR; Corstens FH
    J Nucl Med; 1996 Dec; 37(12):2072-9. PubMed ID: 8970537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.
    Blanco AI; Chao KS; El Naqa I; Franklin GE; Zakarian K; Vicic M; Deasy JO
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1055-69. PubMed ID: 15990009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging.
    Jentzen W; Balschuweit D; Schmitz J; Freudenberg L; Eising E; Hilbel T; Bockisch A; Stahl A
    Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2298-306. PubMed ID: 20625723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma.
    Bal C; Padhy AK; Jana S; Pant GS; Basu AK
    Cancer; 1996 Jun; 77(12):2574-80. PubMed ID: 8640708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial.
    Bohuslavizki KH; Klutmann S; Jenicke L; Kröger S; Buchert R; Mester J; Clausen M
    Cancer Biother Radiopharm; 1999 Oct; 14(5):337-47. PubMed ID: 10850318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
    Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements.
    Liu B; Peng W; Huang R; Tian R; Zeng Y; Kuang A
    Radiology; 2014 Oct; 273(1):211-9. PubMed ID: 24895877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.